For ovarian cancer patients experiencing significant ocular side effects from the ADC mervituximab, switching the dosing schedule from every three weeks to every four weeks can resolve the toxicity by allowing an extra week for recovery.

Clinicians mitigate Belantamab's ocular toxicity by extending dosing intervals to every 8-12 weeks. This is effective due to the drug's long half-life and often allows vision to recover between doses, sometimes even deepening responses without sacrificing disease control.

Due to significant ocular toxicity affecting most patients, the approved starting dose for belantumab is likely not optimal long-term. Effective management requires clinicians to proactively hold, delay, and reduce doses at the first sign of side effects, meaning real-world application will differ from the initial protocol.

Data from the DREAM 7 trial reveals that holding belantamab doses for 12 weeks or longer to manage ocular toxicity did not negatively impact progression-free survival (PFS). Responding patients often maintain their response, challenging the conventional wisdom that strict dosing schedules are paramount for efficacy.

Clinicians are successfully managing Belantamab's primary side effect, keratopathy, by using lower starting doses and extending dosing intervals to every 8 or 12 weeks once a response is seen. This maintains efficacy while significantly improving tolerability for patients.

To manage infection risk and improve quality of life, experts are quickly reducing bispecific antibody dosing frequency (e.g., to monthly) once a response is achieved. This real-world practice deviates from rigid trial schedules to optimize patient outcomes.

The DREAM-7 trial showed a belantumab combination had an overall survival benefit versus a daratumumab regimen, a "premier drug" that previously changed the myeloma treatment landscape. This surprising result establishes a new, higher standard of care and positions belantumab as a top-tier therapy, not merely another option.

Unlike CAR T and bispecifics, the antibody-drug conjugate Belantamab doesn't rely on T-cell function. This makes it a strategic choice for patients who have previously received T-cell engaging therapies, allowing their T-cells to recover while still providing an effective BCMA-targeted treatment.

A major logistical barrier to using belantamab is the required ophthalmic monitoring. However, these exams don't require a specialist ophthalmologist. Routine tests can be performed by a community optometrist, making the drug more accessible for patients and providers outside of large academic centers and lowering adoption barriers.